growing rapidly and is expected to continue
The targeted protein degradation (TPD) market is growing rapidly and is expected to continue its upward trajectory in 2024 making it a biotech trend to follow. This growth is driven by the increasing adoption of advanced technology in therapeutic methods, rising usage of technology for epichaperome inhibitors, and a growing demand for protein degradation strategies in drug discovery. The market is also propelled by the growing need for immunoassays in diagnosing microorganism-based infections and an increasing awareness of the benefits of protein degradation.